Peptide therapeutic - Zambon
Latest Information Update: 31 Oct 2021
At a glance
- Originator Zambon SpA
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Respiratory tract disorders
Most Recent Events
- 27 Oct 2020 Peptide therapeutic - Zambon is available for licensing as of 27 Oct 2020. https://www.zambon.com/en/innovation/partnering
- 27 Oct 2020 Preclinical trials in Respiratory tract disorders in Italy (unspecified route) (Zambon pipeline, October 2020)